|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 心脏康复对心血管疾病保护的研究进展显示文摘心血管疾病发病率和病死率的逐年攀升,原因之一就是现有的医疗体制忽视了心血管疾病发病前的预防和发病后的康复。因此,心脏康复现已成为治疗冠心病及预防患者再发心血管事件的重要手段。本文将对心脏康复对心血管疾病保护的临床应用进展及未来的展望作一简要综述,为优化心脏康复对心血管疾病保护的策略提供新的思路。 | 毕媛晓 方哲 | 2022 | 中国心血管病研究2022，20，5： | 6 |
| 2 | 重组人脑利钠肽联合心脉隆治疗充血性心力衰竭的效果显示文摘目的 分析重组人脑利钠肽联合心脉隆在充血性心力衰竭患者中的治疗效果。方法 选取2021年4月至2023年4月郑州市第二人民医院收治的96例充血性心力衰竭患者为研究对象,按照随机数字表法分为对照组与观察组,每组48例。对照组给予重组人脑利钠肽治疗,观察组加以心脉隆治疗,持续治疗1周。比较两组临床疗效、心功能[左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、N末端B型脑钠肽前体(NT-proBNP)]、不良反应。结果 观察组治疗总有效率为95.83%(46/48),高于对照组[83.33%(40/48)],差异有统计学意义(P<0.05);治疗前,两组各项心功能指标比较,差异未见统计学意义(P>0.05);治疗后,观察组LVESD、LVEDD、NT-proBNP低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05);两组不良反应比较,差异未见统计学意义(P>0.05)。结论 重组人脑利钠肽联合心脉隆在充血性心力衰竭患者治疗中作用明显,可缓解患者症状,加速心功能恢复,且无严重不良反应。 | 韩冰 | 2023 | 临床医学2023，43，12： | 0 |
| 3 | 慢性心力衰竭病人射血分数改善影响因素及列线图预测模型构建显示文摘目的探讨慢性心力衰竭病人临床预后特征及射血分数(LVEF)改善影响因素并构建预测模型,为后续个体化治疗方案制定提供更多参考。方法研究纳入2016年1月至2018年3月于宝鸡市中医医院接受治疗慢性心力衰竭病人共132例,根据LVEF水平分为射血分数改善心力衰竭(HFrecEF)组(14例)、射血分数下降心力衰竭(HFrEF)组(37例)及射血分数正常心力衰竭(HFpEF)组(81例);比较各组临床特征资料及随访终点事件发生情况,采用多因素logistic回归模型评价慢性心力衰竭病人射血分数改善独立影响因素;基于上述独立影响因素构建列线图模型,描绘受试者操作特征(ROC)曲线评估模型预测慢性心力衰竭病人射血分数改善临床效能。结果HFrecEF组年龄显著低于HFrEF组及HFpEF组[(71.08±12.35)岁比(74.15±11.92)岁、(79.26±14.68)岁,P<0.05];HFrecEF组女性比例、扩张型心肌病比例、收缩压(SBP)、舒张压(DBP)及静息心率(HR)水平均显著高于其他两组(P<0.05);HFrecEF组左心室舒张末期内径(LVEDD)、左心室舒张末期容积(LVEDV)、左心房内径(LAD)及合并节段性室壁运动异常比例均显著低于HFrEF组(P<0.05);HFrecEF组LVEDD≤55 mm比例显著高于HFrEF组(P<0.05)。随访时HFrecEF组LVEF水平显著高于入院时(P<0.05);同时随访时HFrecEF组LVEDD、LVEDV及LAD均显著低于入院时(P<0.05);②HFrecEF组病死率和心血管相关病死率均显著低于其他两组(P<0.05);三组猝死率比较差异无统计学意义(P>0.05)。多因素分析结果显示,LVEDD≤55 mm、舒张压>85 mmHg、静息心率>90次/分及无陈旧性心肌梗死均是慢性心力衰竭病人射血分数改善独立影响因素(P<0.05)。根据慢性心力衰竭病人射血分数改善影响因素构建列线图模型,建模组和验证组预测慢性心力衰竭病人射血分数改善AUC分别为0.97[95%CI:(0.94,0.99)],0.94[95%CI:(0.91,0.98)];建模组列线图模型C-index为0.97,提示预测模型具有良好区分度。结论慢性心力衰竭病人如LVEDD≤55 mm、高舒张压、快静息HR及无陈旧性心肌梗死则射血分数改善比例更高,同时HFrecEF往往预后更佳;而基于上述影响因素构建列线图模型能够实现病人射血分数改善精准预测。 | 师彦虎 张帆 孙敏 王音 任璐 | 2024 | 安徽医药2024，28，5： | 0 |
| 4 | Euglycemic diabetic ketoacidosis:A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors显示文摘Sodium-glucose co-transporter 2(SGLT2)inhibitors are an insulin-independent class of oral antihyperglycemic medication and from recently established therapy in chronic heart failure patients.A rare,but potentially life-threatening complication of SGLT2 inhibitor use is euglycemic diabetic ketoacidosis.We described a case of a middle-aged male patient with type 2 diabetes who developed metabolic ketoacidosis after a few days of empagliflozin administration.SGLT2 inhibitor related ketoacidosis presents with euglycemia or only modestly elevated glucose blood concentrations,which causes delayed detection and treatment of ketoacidosis.There are multiple possible risk factors and mechanism that might contribute to the pathogenesis of ketoacidosis.It is implied that SGLT2 inhibitor use and prescription by non-diabetologists(cardiologists,nephrologists,family physicians,etc.)will continue to grow in the future.It is important to inform the general cardiac public about this rare but serious side effect of SGLT2 inhibitors. | Nenad Lakušić Ivana Sopek Merkaš Ana Marija Slišković Dora Cerovec | 2022 | World Journal of Cardiology2022，14，10： | 0 |
| 5 | Quo vadis cardiac rehabilitation;the role of comprehensive cardiac rehabilitation in modern cardiology显示文摘In accordance with the guidelines established by prominent European and global cardiology associations,comprehensive cardiac rehabilitation(CR)stands as an officially endorsed and highly recommended therapeutic approach(class I recommendations;level of evidence A)for a diverse spectrum of cardiac patients.Nevertheless,it is a cause for concern to observe that fewer than 50%of eligible patients are being effectively referred for CR,whether in an outpatient or in-patient setting.Concurrently,studies reveal that a substantial proportion of individuals with atherosclerotic cardiovascular disease maintain unhealthy lifestyles and exhibit suboptimal management of modifiable cardiovascular risk factors,including hypertension,lipid levels,and diabetes.Beyond the conven-tional patient profile encompassing those recovering from acute coronary syndrome with or without percutaneous coronary intervention,as well as patients who have undergone coronary or valvular surgery,contemporary CR now emphasizes specialized subgroups of patients.These include frail elderly patients,the female population with its unique considerations,individuals burdened by multiple cardiovascular comorbidities,those who have developed psychological consequences due to a cardiac illness and particularly those grappling with chronic heart failure.This editorial seeks to offer a state-of-the-art assessment of the significance and role of comprehensive CR within modern cardiology. | Nenad Lakušić Ivana Sopek Merkaš | 2023 | World Journal of Cardiology2023，15，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员